微生物群為本骨骼健康研究
Pendulum Therapeutics 擴大與 Mayo Clinic 的合作
Pendulum Therapeutics 擴展其與全球最受推崇醫療機構之一的梅奧診所（Mayo Clinic）之間的臨床研究合作，探討基於微生物組的介入方式，於乳癌患者的骨骼健康、腸道-皮膚軸線，以及改善更年期過渡等領域的應用。此宣布延續一段始於 2013 年的合作關係。
作為探討骨骼健康、腸道-皮膚軸線及更年期過渡的一部分，此研究合作依賴 Pendulum 旗下針對微生物組的產品組合，以及其於菌株分離、厭氧生產、DNA 定序及臨床驗證方面的專業知識。梅奧診所研究人員將評估這些新的臨床研究。
Pendulum 早已於嚴謹的臨床研究方面擁有良好往績——公司曾研發出 Glucose Control，此產品是首款經臨床證實能夠降低第二型糖尿病患者糖化血色素（A1C）水平的益生菌產品。
英文原文
Pendulum Therapeutics has expanded its clinical research collaboration with Mayo Clinic, one of the most respected medical institutions in the world, to investigate microbiome-based interventions for bone health in breast cancer patients, the gut-skin axis, and improving the menopause transition. This announcement builds on a relationship that began in 2013.
As part of the inquiry into bone health, gut-skin axis, and menopause transition, the research collaboration relies on Pendulum's portfolio of microbiome-targeted products along with its expertise in strain isolation, anaerobic manufacturing, DNA sequencing, and clinical validation. Mayo Clinic investigators will evaluate these new clinical studies.
Pendulum already has a track record of rigorous clinical research, having developed Glucose Control, the first probiotic clinically shown to reduce A1C in people with type 2 diabetes.
- 來源
- Trend Hunter
- 發布
- 2026-05-15
- 品類
- Mobile
- 出處
- prnewswire